Eisai to Level to Latest Data on Lemborexant and Unusual Orexin Receptor Agonist E2086 at The World Sleep 2025

TOKYO, September 4, 2025 – (JCN Newswire) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced on the fresh time that the company will insist a total of 11 presentations, alongside side scientific files on the selective orexin 2 receptor agonist (OX2R)E2086 and essentially the latest findings on its in-condominium discovered orexin receptor antagonist lemborexant (product title: DAYVIGO®) on the World Sleep Congress (World Sleep 2025) to be held in Singapore from September 5 to 10.Key presentations consist of results from the Section Ib scientific glimpse exploring the efficacy (Proof of Mechanism) of E2086 in other folks identified with narcolepsy form 1 (NT1) and the Section IV scientific glimpse(SELENADE Stare) investigating the manufacture of lemborexant in other folks whose insomnia modified into once comorbid with depressive episodes of fundamental depressive dysfunction and bipolar dysfunction (Poster 3-133…
Read More